Skye Bioscience, Inc. (SKYE)
| Market Cap | 51.44M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -42.37M |
| Shares Out | 30.99M |
| EPS (ttm) | -1.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,802,769 |
| Open | 2.030 |
| Previous Close | 1.900 |
| Day's Range | 1.650 - 2.100 |
| 52-Week Range | 1.140 - 5.960 |
| Beta | 2.35 |
| Analysts | Strong Buy |
| Price Target | 14.75 (+788.55%) |
| Earnings Date | Nov 6, 2025 |
About SKYE
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Die... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for SKYE stock is "Strong Buy." The 12-month stock price target is $14.75, which is an increase of 788.55% from the latest price.
News
Skye Bioscience, Inc. - Special Call
Skye Bioscience, Inc. - Special Call Company Participants Bernie Hertel Punit Dhillon - President, CEO, Secretary & Director Puneet Arora - Chief Medical Officer Tu Diep - Chief Operating Officer Chri...
Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 150 points on Monday.
Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss
Skye Bioscience Inc. (NASDAQ:SKYE) stock sank on Monday after the company released topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab.
Skye Bioscience's obesity drug fails to meet main goal of mid-stage study
Skye Bioscience said on Monday its experimental obesity drug did not meet the main goal of a mid-stage study.
Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial
Nimacimab monotherapy did not meet its primary endpoint for weight loss; preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosin...
Skye Bioscience: Promising Nimacimab Data Supports Buy Rating
Skye Bioscience is rated Buy, driven by nimacimab's strong safety, durable weight-loss profile, and upcoming Phase 2a results. SKYE's nimacimab targets the expanding anti-obesity market, showing poten...
Could This New Drug Be The Safer Way To Fight Obesity?
On Friday, Skye Bioscience, Inc. SKYE announced the presentation of results from the Phase 1b study of nimacimab in subjects with metabolic-associated steatotic liver disease (MASLD) at the European A...
Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting
Novel CB1 inhibitor Phase 1b data highlights lack of neuropsychiatric adverse events and favorable gastrointestinal tolerability Novel CB1 inhibitor Phase 1b data highlights lack of neuropsychiatric a...
Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Skye Bioscience, Inc. (NASDAQ:SKYE) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 7:00 AM EDT Company Participants Punit Dhillon - President, CEO, Secretary & Director Co...
Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data
On Thursday, Skye Bioscience Inc. SKYE reported positive results from two preclinical obesity studies testing nimacimab, a peripherally-acting CB1-inhibiting monoclonal antibody.
Skye Bioscience, Inc. (SKYE) Virtual KOL Event Transcript
Skye Bioscience, Inc. (SKYE) Virtual KOL Event Transcript
Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model
Skye shares new preclinical DIO data at virtual KOL event Nimacimab + tirzepatide demonstrates over 40% weight loss in multiple preclinical DIO studies Nimacimab demonstrates durable post-treatment we...
Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study
SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other ...
Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout
Virtual KOL event will begin at 8:00 AM ET on Thursday, September 4, 2025 Virtual KOL event will begin at 8:00 AM ET on Thursday, September 4, 2025
Skye Bioscience to Participate in Upcoming Investment and Medical Conferences
SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other m...
Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript
Skye Bioscience, Inc. (NASDAQ:SKYE) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Kaitlyn Melanie Arsenault - Chief Financial Officer Puneet S. Arora - Chief Medical...
Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G...
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other m...
Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing
Skye Bioscience's Nimacimab remains a promising peripheral CB1 antibody for obesity with lean-mass preservation and fewer GI issues. Nimacimab's Phase 2a topline is expected by Q3-Q4 2025, which is it...
Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other m...
Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions
SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other m...
Skye Bioscience to Participate in Upcoming Investment Conferences
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other me...
Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
Proprietary formulation technology being applied to potentially enhance properties of nimacimab Proprietary formulation technology being applied to potentially enhance properties of nimacimab
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health...
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity
• This model demonstrates that central inhibition of CB1 is not required for weight loss • Anti-CB1 inhibiting antibody, nimacimab, showed greatest peripheral restriction compared with monlunabant and...